The company reiterated its full-year 2024 sales guidance of roughly $4 billion, which includes revenue from the expected launch of its RSV vaccine.
Source: https://www.cnbc.com/2024/05/02/moderna ... -2024.html
Moderna loses less than expected as Covid vaccine sales beat estimates, cost cuts take hold
